People
Scientific Advisory Board

World-renowned oncology expert, has registered more than 15 of the world’s top cancer drugs, over 35 years in oncology drug development
▪ Former CMO of Celgene where he presided over the registration of drugs including Abraxane, Revlimid, Vidaza, Istodax, and Taxotere
▪ Board member in various biotech companies including Transgene, Halozyme, Celator Pharmaceuticals, and CRO IDDI
▪ Author of more than 70 articles in peer-reviewed
▪ Senior advisor to the board of Quercis Pharma AG and Board Observer.

Major contributor to the understanding of the mechanism of platelet granule release and its role in thrombus
▪ M.D. and Ph.D. from NYU School of Medicine as well as M.Sc from Harvard Medical School
▪ Associate Director of the Translational Research Center in Thrombosis and Hemostasis
▪ Member of the Hemostasis and Thrombosis NIH Study Section
▪ Member of the American Society for Clinical Investigation

Former Head of the Laboratory of Neurodegeneration at Pasteur, Montevideo and performing research on the cellular and molecular mechanisms of brain aging
▪ M.D. from the University of the Republic (Uruguay) and Ph.D. from Collège de France
▪ Member of the National Academy of Science of Uruguay and of the Third World Academy of Science
▪ Former President of IIBCE Board of Directors
▪President of the National Council of Science and Technology between 2006-2009

World renowned oncologist, specialist in pancreatic cancer
▪ Professor of Medicine at Cornell Medical School and Chief of the Division of Hematology and Medical Oncology at Weill Cornell Medicine and New York-Presbyterian/Weill Cornell Medical Center
▪ Previously Clinical Director of the Rosenberg Clinical Cancer Center at Beth Israel Deaconess Medical Center, Harvard
▪ Member of the Board of PANCAN
▪ Author of more than 220 articles in the top tier peer-reviewed journals

Expert on nano-sensors for in vivo tumor profiling
▪ Professor at ETH Zürich heading the Responsive Biomedical Systems Lab
▪ Former researcher at MIT on nanosensors for in vivo tumour profiling
▪ Co-founder of MagnebotiX
Board of Directors

▪Serial entrepreneur for more than 20 years. Started and successfully built/sold more than 10 companies
▪ Authored multiple drug patents and trademarks
▪ Has been studying naturally occurring small molecules as disease prevention agents with an emphasis on flavonoids for 20+ years
▪ Founded and built biotech/pharma business and bundled it into Quercis Pharma AG in 2019
▪ Doctor of Science (hc)

▪ Cardiologist and Former Minister of Health in France and Under-Secretary-General of the United Nations
▪ Founder of Unitlife and former chairman of the Executive Board of UNITAID

▪Chairman and CEO, Atanis Biotech AG
▪Prof. Emeritus at Harvard Medical School following 22 years of full professorship in Medicine
▪Immunologist, discovered Calcium Ion Channel
▪Managing Director of iXLife, a private investment fund with12 active healthcare investments
▪Board Member in Biotech and Big Pharma

▪ Former Chief Strategy Officer Vifor Pharma where he was driving the growth strategy, creating value through in-house development and a series of licensing deals & acquisitions.
▪ Board member in various biotech companies including 4TEEN4, Adrenomed and HICT
▪ 25+ years of experience as pharma executive at AMGEN and Vifor Pharma in commercial, strategic and R&D roles
▪Involved in selling VIFOR to CSL for $11.75Bn in December 2021
Board Observers

▪ Former Chairman of Quercis
▪ 25 years of experience in strategy consulting & investment management
▪ Partner and Managing Director at Cevian Capital for 12 years with 7 years at McKinsey’s Corporate Finance practice
▪ Seven years at McKinsey’s Corporate Finance practice, ultimately as Associate Principal
▪CEO of Spectrum Value Management
▪Board Member at Holcim, CANCON

▪Board member in various biotech companies including Transgene, Halozyme, Celator Pharmaceuticals, and CRO IDDI
▪Chairman of Scientific Advisory Board
Executive Team

▪Serial entrepreneur for more than 20 years. Started and successfully built/sold more than 10 companies
▪ Authored multiple drug patents and trademarks
▪ Has been studying naturally occurring small molecules as disease prevention agents with an emphasis on flavonoids for 20+ years
▪ Founded and built biotech/pharma business and bundled it into Quercis Pharma AG in 2019
▪ Doctor of Science (hc)

▪ Over 40 years in natural products and pharmaceutical development specializing in flavonoid research and clinical program support.
▪ Leads process optimization for API manufacturing. Holds multiple patents for flavonoid compounds and applications. Champions innovative approaches in translational medicine to advance global health initiatives.

▪ Over 35 years of experience in the pharmaceutical and biotech industry
▪ Former Chief Medical Officer and Head of R&D at Vifor Pharma
▪ Previous Head of Clinical Research at Novartis OTC
▪ 20 years at Bayer in R&D
▪ Medical Doctor

▪ Over 28 years of clinical development experience in clinical and safety operations, regulatory submissions, company governance, and quality management systems
▪ Served as medical leader and safety leader overseeing complex development phases of innovative products across multiple therapeutic indications in both Europe and in the U.S.
▪ Co-founder and former Chief Executive Officer of an international CRO specialized in the design and execution of effective drug development plans.
▪ Medical Doctor

▪ Over 20 years of experience in senior leadership positions in the nutraceutical and pharmaceutical fields
▪ Former General Manager for Catalent
▪ Former CEO of Nutravail which was sold to private-equity backed Bettera Brands
▪ Part of leadership team that sold Bettera Brands to Catalent for $1B
▪ Practiced law as a commercial litigator before transitioning to a business role